Rural Health Information Hub Latest News

Updated Medicaid Eligibility for COFA Migrants

Effective December 27, 2020, migrants under the Compact of Free Association (COFA) may be newly eligible for Medicaid if they meet all of the eligibility criteria in their state. COFA migrants are generally citizens of the Marshall Islands, Federated States of Micronesia, and Republic of Palau who are lawfully residing in one of the U.S. states or territories. Under the new eligibility criteria, COFA migrants are now considered qualified non-citizens (QNC) for the purposes of Medicaid eligibility and do not have to wait for five years after receiving their status before qualifying for Medicaid coverage, if otherwise eligible. This policy change does not apply to coverage through separate Children’s Health Insurance Program (CHIP) programs, except for states that have elected to cover children and/or pregnant women in CHIP under the CHIPRA 214 option.

Currently, COFA migrants who apply at the Federally-Facilitated Exchange (FFE) will not be found eligible for Medicaid, as the system does not consider COFA migrants to be QNCs for purposes of Medicaid eligibility. Instead, COFA migrants may be found eligible for Marketplace coverage with advance payments of the premium tax credit (APTC) or cost-sharing reductions (CSRs), if otherwise eligible. CMS is actively working on system changes to determine correct eligibility for these consumers at the Marketplace, and anticipates a release in early summer 2021.

Until the system changes at the FFE are finalized, CMS recommends that consumers apply directly with their state Medicaid agencies to determine their eligibility for Medicaid. Once consumers receive a determination of eligibility for Medicaid, they should return to the Marketplace to end their QHP coverage with financial assistance if they are found eligible for Medicaid and do not want to pay full cost for their share of the Marketplace coverage. This is because consumers who are enrolled in Medicaid or CHIP that counts as qualifying coverage (also known as minimum essential coverage, or MEC), are not eligible for APTC or CSRs to help pay for the cost of a Marketplace plan premium and covered services. The FFE will not take action on a consumer’s behalf to end their Marketplace coverage if they are found to be Medicaid eligible by their state due to this policy update.

NIOSH COVID-19 Resources

As part of NIOSH’s efforts to keep our readers up to date on the CDC and NIOSH COVID-19 response, here is a summary of new information available:

Vaccination Resources

Post-vaccination Considerations for Workplaces

CDC has developed information for workplaces to help them properly evaluate and manage employees who have signs and symptoms after receiving a COVID-19 vaccine. Occupational health programs and public health officials can use the strategies, which apply to employees working in various settings.

Ventilation Resources

Upper-room Ultraviolet Germicidal Irradiation
CDC published this new webpage with information on upper-room ultraviolent germicidal irradiation (UVGI), which can be effective at reducing exposures to SARS-CoV-2 in some group settings. SARS-CoV-2 is the virus that causes COVID-19. UVGI uses ultraviolet (UV) energy to kill viral, bacterial, and fungal organisms. Other ventilation strategies, such as fans that bring in outdoor air, high-efficiency particulate air (HEPA) filter systems, and open windows, can also help reduce infectious viral particles in the air.

 

 

For More Information

For more information, please visit the COVID-19 webpage. To stay up to date on new developments, sign up for the COVID-19 newsletter.

 

 

HHS Announces Commitments from Partners to Encourage Latino Consumers to Enroll in Health Insurance Coverage through HealthCare.gov

U.S. Department of Health and Human Services (HHS) Secretary Xavier Becerra announced commitments from national organizations to support Latino outreach and enrollment efforts during the current Special Enrollment Period (SEP) made available on HealthCare.gov by President Biden due to the COVID-19 Public Health Emergency. As part of the Latino Week of Action April 18 – 24, these organizations and HHS will share information with Latino consumers and use social media to encourage them to enroll in affordable, quality health plans through HealthCare.gov.

“Helping communities take advantage of reduced costs on quality health care coverage is a priority for this Department. In addition to putting our money where our mouth is, we are partnering with key organizations representing the Latino community to engage their knowledge and network to promote enrollment in quality, affordable health insurance coverage during this Special Enrollment Period,” said HHS Secretary Becerra. “To the many Latinos who may have lost health care coverage during the pandemic, I am here to tell you that ‘help is here.’ Health care coverage is more affordable for people and assistance is available if you need help finding a health plan that best meets your needs.”

CMS: Vaccine Resources: 4/16/21 – J&J Vaccine Update and HHS Key Messages

As COVID-19 vaccines continue rolling out across the country, CMS is taking action to protect the health and safety of our nation’s patients and providers and keeping you updated on the latest COVID-19 resources from HHS, CDC and CMS.

With information coming from many different sources, CMS has up-to-date resources and materials to help you share important and relevant information on the COVID-19 vaccine with the people that you serve. You can find these and more resources on the COVID-19 Partner Resources Page and the HHS COVID Education Campaign page. We look forward to partnering with you to encourage our beneficiaries to get vaccinated when they have the opportunity. For more information, visit the CMS COVID-19 Policies and Guidance page.

Information for Providers

J&J COVID-19 Vaccine: Health Alert

The CDC issued a Health Alert, about the CDC and FDA’s recommended pause in the use of the J&J COVID-19 vaccine, in part, to ensure that the health care provider community is aware of the potential for adverse events and can provide proper management due to the unique treatment required with this type of blood clot. This alert includes specific recommendations for clinicians.

Information for Partners

A message from the COVID-19 Community Corps::

Tuesday night, you and nearly 2,500 fellow trusted messengers joined Dr. Fauci and me to discuss the Johnson & Johnson (J&J) vaccine recommended pause. Thank you for being there. Your leadership in sharing the latest information about COVID-19 vaccines with the communities you serve and engage is essential to addressing this pandemic. I’d like to take a moment to summarize our discussion:

  • On Tuesday (4/13), the Centers for Disease Control and Prevention (CDC) and the U.S. Food and Drug Administration (FDA) announced they are reviewing data involving a small number of reported cases of a rare and serious type of blood clot in individuals after receiving the J&J vaccine. FDA and CDC, out of an abundance of caution, recommended a pause in the use of the J&J vaccine as they review this data.
  • Based on what we know now, these blood clots are extremely rare. At the time of the announcement, a small number of cases (6) were reported out of the nearly seven (7) million doses of the J&J vaccine administered so far in the United States.
  • If you received the J&J vaccine more than three weeks ago, your risk of developing a blood clot is very low. If you got this vaccine within the last three weeks, your risk of developing a blood clot is also very low. That said, you should be on the lookout for possible symptoms of a clot, which the CDC describes, here.
  • The news about the J&J vaccine pause does not affect the two other vaccines that are widely used in the United States – Pfizer and Moderna. More than 100 million people in the U.S. have been vaccinated safely with these vaccines over the past several months.
  • We are still confident in the overall supply of COVID-19 vaccines for the country. The Administration has secured enough Pfizer and Moderna doses for 300 million Americans and there is more than enough supply to continue the current pace of vaccinations of three (3) million shots per day.
  • For people who already have appointments for J&J vaccines, state and federal partners are working to get these appointments rescheduled for a Pfizer or Moderna vaccine.
  • The decision to recommend a pause in administration of the J&J vaccine shows the rigorous steps that the FDA are taking to ensure that the American people have clear and transparent information about the safety and effectiveness of these vaccines. Americans should be confident that even when the occurrence of side effects are extremely rare, as is the case here, the CDC and FDA will take every necessary step to communicate those to the public.
  • Yesterday (4/14), the Advisory Committee on Immunization Practices (ACIP) held a public meeting to review in detail the information we have so far, which you can watch here. The Committee will reconvene as quickly as possible in the next two weeks to review any additional scientific evidence and deliberate further. CDC and FDA will carefully consider the Committee’s recommendations when they are made. I appreciate ACIP convening quickly and experts providing advice that prioritizes safety.
  • Here’s the bottom line: The COVID-19 vaccines have already saved lives, and we still have vaccine options that are safe and effective, and Americans should continue to get vaccinated as soon as possible.
  • As a resource, more information about the safety of COVID-19 vaccines can always be found here.

I invite you to watch and share these resources with your community:

Thank you for your continued partnership in protecting the health of our nation.

Dr. Vivek Murthy

Surgeon General of the United States

Pennsylvania Announces Grant Opportunities to Provide Employment Support Services for Individuals with Substance Use Disorder

The Pennsylvania Department of Drug and Alcohol Programs (DDAP) announced the availability of $2.7 million in funding for entities to deliver employment support services to individuals in recovery from substance use disorder (SUD) seeking to enter the workforce.

“A key component to an individual’s sustained recovery is steady, reliable employment,” said DDAP Secretary Jen Smith. “To date, we have significantly expanded access to treatment, and we are starting to shift our focus to the entire continuum of care. These grants will enable organizations to give individuals the necessary tools to succeed after treatment and empower their recovery.”

The grants are part of $55 million in federal funding awarded to Pennsylvania through the Substance Abuse and Mental Health Services Administration’s (SAMHSA) Substance Abuse Prevention and Treatment Block Grant Program COVID-19 Supplemental Awards. The funding spending plan submitted by DDAP is currently pending approval by SAMHSA. More information will be shared about this funding and supporting projects as it becomes available.

Eligible applicants can find the grant application and project summary on the DDAP website here. Five to eight grants will be awarded up to $400,000 for a wide variety of eligible items, including:

  • Vocational assessments;
  • Resume writing;
  • Interviewing skills;
  • Job placement; and
  • Transportation assistance related to employment.

All applications must be submitted via email to RA-DAGrantsMgmt@pa.gov by 12:00PM on Monday, May 17, 2021. Applications will be competitively reviewed and scored based upon the applicant’s adherence to the funding announcement guidelines, and timely submission to DDAP. Additionally, awarding of the funds is contingent upon the approval of DDAP’s funding spending plan by SAMHSA.

Questions regarding the grants and the application process should be forwarded to RA-DAGrantsMgmt@pa.gov.

Throughout the Wolf Administration’s second term, DDAP is placing a heavy focus on reducing stigma associated with substance use disorder, intensifying primary prevention efforts, strengthening treatment systems, and empowering sustained recovery. The aim of these efforts, laid out in DDAP’s 2019-2022 State Plan, will be to positively influence the knowledge and behavior around the topic of addiction.

For more information about the work the Wolf Administration is doing to combat the opioid crisis, visit pa.gov/opioids.

Comments Requested on Proposed Changes to Four Medicare Payment Rules – all comments due June 7

CMS published proposed changes to how Medicare pays for services and measures quality of care for four types of providers in FY 2022:  Skilled Nursing FacilitiesHospice ProvidersInpatient Psychiatric Facilities, and Inpatient Rehabilitation Facilities.  These rules also include Requests for Information on ways to attain health equity for all patients and the use of Fast Healthcare Interoperability Resources (FHIR) standards to digitally submit quality information.

Comments Requested: Rural Telehealth and Healthcare System Readiness for Disaster – May 7

The National Quality Forum (NQF) released an overview of policies and quality measures related to telehealth, healthcare system readiness, and rural health outcomes during and after disasters. The review of these policies will inform a new framework for measuring the quality of care provided by telehealth in rural areas.  NQF members and the public are invited to submit comments by 6:00 pm ET on Friday, May 7.

Vaccine Hesitancy for COVID-19: State, County, and Local Estimates

To support state and local outreach efforts, HHS researched federal survey data to predict vaccine hesitancy rates down to the county level.  There are two Excel spreadsheets:  one presents state and county estimates of the proportion of adults who describe themselves as “probably not” (Hesitant) or “definitely not” (Strongly Hesitant) going to get a COVID-19 vaccine once one is available to them, and the other presents select sociodemographic and geographic factors by county that can be examined together with the estimates of vaccine hesitancy. See the map here.